
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals Inc. demonstrates a strong potential for growth due to the positive results from its clinical trials for etripamil, particularly regarding patient-reported outcomes such as symptom relief and treatment satisfaction, which showed statistically significant improvements. The favorable results, including high scores on the TSQM-9 effectiveness domain and global satisfaction, suggest a promising acceptance of etripamil among patients with cardiovascular conditions. Furthermore, the belief in the manageability of challenges identified in the CRL indicates that the company is positioned for future approval, enhancing its long-term outlook for investors.
Bears say
Milestone Pharmaceuticals has faced significant regulatory and clinical setbacks that have adversely impacted investor confidence in the company's stock. These challenges, coupled with a heightened diligence bar for funding in the current market environment, contribute to a negative outlook on the stock's potential for recovery. Moreover, the possibility of market competition undermining demand for etripamil and future candidates poses further risk to projected revenues.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares